Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

A Study to Test the AdaptDx Pro Agreement in Rod Intercept Time With the AdaptDx in Healthy Subjects With Normal Vision (FlashBack)

AdaptDx, Inc. · NCT07803588

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 22–49 · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
24
US sites recruiting
1
Study start
September 15, 2026
Record last updated
September 3, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to test the AdaptDx Pro agreement in Rod Intercept (RI) time with the AdaptDx tabletop (AdaptDx) in healthy subjects with normal vision.

Being studied: AdaptDx Tabletop vs AdaptDx Pro

Conditions: Healthy Adult Participants

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

Subjects enrolled in the study will be required to meet all the following criteria for both eyes:

  • Male or female between the ages of 22 and 49 (inclusive) at Visit 1
  • ETDRS BCVA letter score of 85 (Snellen equivalent of 20/20) or better at Visit 1
  • Able to communicate well with the Investigator and able to understand and comply with the requirements of the study
  • Informed of the nature of this study and has provided written informed consent in accordance with institutional, local and national regulatory guidelines

Exclusion Criteria

  • Unable to follow simple instructions, operate a response button or maintain attention for 20 minutes
  • Diagnosis or history of any ocular disease or disorder
  • Serious medical illness that will prevent the subject from performing study activities (including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease) or, in the judgement of the Investigator, is likely to require surgical intervention or hospitalization at any point during the study
  • Presence of or history of malignancy within the past year of Visit 1 other than non-melanoma skin or squamous cell cancer or cervical carcinoma in-situ
  • Is non-ambulatory
  • History of drug, alcohol or substance abuse within 3 months prior to Visit 1
  • Has received an investigational drug or treatment with an investigational device within 3 months prior to Visit 1
  • In the opinion of the Investigator, is unlikely to comply with the study protocol

Recruiting US locations

  • Retina Consultants San Diego

    San Diego, CA 92101

    Site contact: Nikolas London, MD, FACS · 858-451-1911 · london@rcsd.com

Study contacts (from the official record)

  • Cindy Croissant VP, Clinical Operations, BS, MBA · 858 397 1021 · ccroissant@opzira.com
A Study to Test the AdaptDx Pro Agreement in Rod Intercept Time… (NCT07803588) | Bored Studies